LTS and Revive Therapeutics Ltd. are pleased to announce that they have entered into a feasibility agreement to develop and manufacture a proprietary oral psilocybin thin film strip for the Company’s clinical and commercial initiatives to evaluate in mental illness, neurological and substance abuse disorders.

The United States Patent and Trademark Office has issued the notice of allowance for its U.S. Patent Application entitled "Transdermal Therapeutic System Containing Asenapine“.

LTS Lohmann Therapie-Systeme AG has entered into a research collaboration agreement for the evaluation of LTS Micro Array Patch (MAP) technology.

Dr. Sebastian Braun will present “Dissolvable microarray systems - An industry view regarding development and manufacturing of a new dosage form”.

Microneedle systems - is easier to ship, easier to use and painless for the patient. Join this free web seminar to understand the advantages of microneedle systems.